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STAT3Proliferation of vascular smooth muscle cells (VSMCs) plays an important role in restenosis, a disease character-
ized by smooth muscle cell hyperplasia and neointimal formation. How proliferation signals are controlled to
avoid restenosis is not fully understood. Here we report that TIPE2, the tumor necrosis factor (TNF) α-induced
protein 8-like 2 (TNFAIP8L2), suppresses injury-induced restenosis by inhibiting VSMCs proliferation. TIPE2
was signiﬁcantly upregulated in VSMCs in response to PDGF-BB stimuli and injury. Enforced TIPE2 expression
signiﬁcantly suppressed VSMCs proliferation and cell cycle progression, whereas TIPE2 deﬁciency in VSMCs
promoted cell proliferation and upregulated the expression of Cyclins D1 and D3. TIPE2 likely regulated VSMC
proliferation via Rac1-STAT3 and ERK1/2 signaling pathways. It blocked STAT3 activation and nuclear transloca-
tion in a Rac1-dependent manner. As a result, TIPE2-deﬁcient VSMCs exhibited enhanced proliferation whereas
TIPE2-deﬁcient mice developed more severe restenosis in response to vascular injury. Conversely, adenovirus-
mediated gene transfer of TIPE2 signiﬁcantly reduced injury-induced restenosis in mice. These results indicate
that TIPE2 plays a suppressive role in injury-induced restenosis and may serve as a new therapeutic target for
treating the disease.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Proliferation of vascular smoothmuscle cells (VSMCs) plays a critical
role in the development of vascular diseases such as restenosis follow-
ing percutaneous coronary interventions (PCI) or angioplasty [1,2].
Although drug-eluting stents and continuing dual antiplatelet therapy
can inhibit VSMC proliferation and subsequent restenosis, their clinical
beneﬁts are still limited because of the severe clinical complications,
such as acute thrombocytopenia and late stent thrombosis [3–6]. There-
fore, the identiﬁcation of new antiproliferativemolecules holds promise
for new therapeutic strategies for treating restenosis following angio-
plasty and PCI.
TNFAIP8L2 (TIPE2), the tumor necrosis factor (TNF)-α-induced pro-
tein 8 (TNFAIP8, TIPE) like 2, is a member of the TNFAIP8 family that
plays important roles in controlling inﬂammation and tumorgenesis
by suppressing RAS signaling [7–10]. Its deﬁciency in 129/J mice causes
fatal inﬂammatory diseases [8] and abnormal expression in humans is
associated with many kinds of diseases, such as hepatocellular carcino-
ma [7,10], stroke [11], HBV infection [12] and atherosclerosis [13,14].
Our previous studies showed that TIPE2 plays atheroprotective roles, Department of Immunology,
12, PR China. Tel.: +86 531by negatively regulating ox-LDL-induced inﬂammatory responses
in macrophages [13,14]. Furthermore, TIPE2 could inhibit neointima
formation by regulating phenotypic switching of VSMCs during athero-
genesis [13,14]. However, whether TIPE2 plays a role in the vascular re-
modeling process in response to injury is still unknown.We report here
that TIPE2 could suppress experimental restenosis by inhibiting vascu-
lar remodeling after injury.2. Materials and methods
2.1. Mice
All experiments with animals were performed in accordance with
the National Institutes of Health Guide for the Care and Use of Laborato-
ry Animals (NIH publication numbers 23–80, 2011) and the Animal
Management Guidelines of the Chinese Ministry of Health (document
no. 55, 2001). All animal procedures were approved by the Animal Eth-
ical Committee of the Shandong University. Male wide type (WT)
C57BL/6J mice were purchased from Shanghai Laboratory Animal
Center of the Chinese Academy of Science, and were 8–12-weeks-old
at the time of the entry into the study. The male TIPE2-deﬁcient
(TIPE2−/−) C57BL/6J mice of the same age were as described previously
[8]. All mice were housed in the Animal Facilities of the Shandong Uni-
versity, under pathogen-free condition.
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TIPE2−/− orWTmicewere utilized to perform carotid artery ligation
to induce restenosis as described previously [15]. Mice were anesthe-
tized with sodium pentobarbital (50mg/kg, i.p.). The adequacy of anes-
thesia was monitored by testing respiration rate, mucous membrane
color and tactile stimulus response. After adequate anesthesia, the left
carotid artery was completely ligated just proximal to the carotid bifur-
cation. The right carotid artery served as an uninjured control. Both the
left and right carotid arteries were collected at 7, 14, and 21 days after
injury. Before isolation of tissues, mice were deeply anesthetized with
5% isoﬂurane and rapidly perfused via the aorta with 37 °C warm saline
followed by 4% paraformaldehyde. The carotid artery was removed and
ﬁxed in 4% paraformaldehyde overnight, then embedded in optimal
cutting temperature (OCT) compound (Tissue-Tek; Sakura Finetek).
Cross sections at 5 μm thickness were prepared from tissues 1.0 mm
proximal to the ligature of the aortic arch. These sections were located
at ~2.0 mm proximal to the ligature, and each section was 300 μm
apart (i.e., 1700 μm, 2000 μm, and 2300 μm proximal to the ligature)
[16]. Sections were subjected to hematoxylin (Sigma Diagnostics) and
eosin (Merck Diagnostica) staining, and the areas of the intima and
media were measured by Image-Pro Plus software (Media Cybernetics,
Silver Spring, MD). Morphologic analysis was performed for 3 sections
per artery. Six mice for each genotype were analyzed.
All mice received intraperitoneal injection of the thymidine analog
5-ethynyl-2′-deoxyuridine (EDU, Invitrogen) at 5 μg/g of body weight
for 12 h prior to euthanasia. Some sections were washed in PBS and
permeabilized using 0.5% Triton X-100; the incorporated EDUwas conju-
gated to Alexa Fluor 488-azides using the Click-IT reagent kit (Molecular
Probes, Invitrogen), and stained with McAb anti- SMαA (Millipore,
1:200) and rhodamine-conjugated secondary Abs (Molecular Probes,
Invitrogen). After the cell nuclei were stained with 4′, 6-diamino-2-
phenylindole (DAPI, Roche), the sections were visualized by ﬂuorescent
microscopy (Olympus BX51, Japan), and the percentage of EDU-positive
VSMCswas analyzed by Image-Pro Plus software (Media Cybernetics, Sil-
ver Spring, MD).
Alternatively, sections were stained with TUNEL (Roche) to detect
apoptotic cells. The TUNEL Indexwas calculated as the ratio of thenumber
of TUNEL-positive nuclei to the total nuclei number in the section.
2.3. Recombinant adenovirus and infection
Recombinant adenovirus encoding murine TIPE2 (mTIPE2) and GFP
were prepared by Sinogenomax corporation (Beijing, China). WT mice
(n = 20) with complete ligation in the left carotid artery were in situ
infectedwithmTIPE2-expressed adenovirus or GFP-expressed adenovi-
rus (1 × 109 pfu). Mice were subjected to a second infection by tail vein
injection at day 21 and sacriﬁced at day 42. Cross-section preparation
and morphologic analysis were performed as described above.
2.4. Cell culture of VSMCs
Primary murine VSMCs used in this study were obtained from the
aorta ventralis of 8-week-old male WT or TIPE2−/−mice (deeply anes-
thetized with 5% isoﬂurane) by enzymatic digestion (type I collagenase
and type III elastase, Sigma) according to a previous study [14]. Quies-
cent cells cultured in serum-free DMEM for 48 h were collected and
stainedwith anti-SMαA; ﬂow cytometric analysis was performed to de-
termine the percentage of positive cells. VSMCs (SMαA-positive Cells)
from passages 3 to 7 were used in this study.
2.5. Plasmids and transfection
pEGFP-mTIPE2, pRK5-ﬂag-mTIPE2-WT and pRK5-ﬂag-mTIPE2-
R24A were constructed in our lab as described previously [9]. pRK5-
myc-Rac1-Q61L and pMXs-STAT3-C were purchased from Addgene.Murine STAT3-C cDNA was subcloned from pMXs-STAT3-C. The
primers used for PCR were STAT3F-BamH1 (cgcggatccgccaccATGGCT
CAGTGGAACCAGCTG) and STAT3R-EcoR1 (ccggaattcTCACATGGGGG
AGGTAGCACA) [17]. The PCR product was digested with BamH1 and
EcoR1, cloned into pCMV-N-HA vector, and further conﬁrmed by se-
quencing (Invitrogen).
Transfection was performed using Lipofectamine 2000 (Invitrogen)
according to the manufacturer's protocol. WT VSMCs transfected with
Flag-mTIPE2 or Flag-mTIPE2-R24A were used for determining signal
pathway activation, D type Cyclin expression or cell proliferation.
HEK293 cells transfected with HA-STAT3-C along with Flag-mTIPE2,
Rac1-siRNA, or Flag-mTIPE2 plus Myc-Rac1-Q61L were used for
STAT3-C nucleus translocation analysis.
2.6. Quantitative real-time PCR
Total RNAwas extractedwith TRIZOL reagent (Invitrogen) according
to the protocol. Single-strand cDNA was synthesized using hexamer
primers (Promega). cDNA was used as templates for the ampliﬁcation
of genes concerned. Speciﬁc primers used for Quantitative real-time
PCR assays were 5′-GCGTACCCTGACACCAATCTC-3′ (Sense) and 5′-
CTCCTCTTCGCACTTCTGCTC-3′ (Antisense) for Cyclin D1, 5′-TGGATCGC
TACCTGTCCTG-3′ (Sense) and 5′-CCTGGTCCGTATAGATGCAAAG-3′
(Antisense) for Cyclin D3, 5′-TCAGAAACATCCAAGGCCAGAC-3′ (Sense)
and 5′-CGGACCGACCAGCCATTTTAC-3′ (Antisense) for mTIPE2, 5′-
TGCGTGACATCAAAGAGAAG-3′ (Sense) and 5′-TCCATACCCAAGAA
GGAAGG-3′ (Antisense) for β-actin. Each sample was run in triplicate.
The primers used throughout this study were synthesized by Invitrogen
Corporation.
2.7. Proliferation
VSMCs (2 × 103 cells/well) were cultured in 96-well dishes over-
night and then allowed to proliferate in the absence or presence of
10 ng/mL PDGF-BB (Pepro Tech) in DMEM (GIBCO-BRL) medium con-
taining 10% FBS (Gibco-BRL). Cell proliferation was measured at differ-
ent time intervals over a period of 3 days using Cell Counting Kit-8
reagent (CCK-8, Dojindo) as described by the manufacturer. At each
time point, 10 μL of CCK-8 reagent was added to each well 1 h before
the end of incubation. The optical density (OD) value of each sample
was measured at a wavelength of 450 nm on a microplate reader
(Model 680, BIO-RAD).
2.8. Flow cytometry analysis
VSMCswere cultured in 6-well dishes for 24 h. Then cells weremade
quiescent by incubation with serum-free DMEM for 24 h, and
allowed to grow for another 24 h in the absence or presence of
PDGF-BB (10 ng/mL). Cells were collected, ﬁxed in ice-cold ethanol,
and treated with 100 μg/mL RNase A solution in 37 °C for 30 min.
Cells were then washed and incubated with 50 μg/mL propidium io-
dide (PI, Sigma) containing 0.2% Triton X-100 for 30 min. PI incorpo-
ration was determined by ﬂow cytometry (FC-500 MCL/MPL,
BECKMAN).
2.9. Western blot and antibodies
Western blotting was performed as described previously [14].
The following primary antibodies were used: anti-SMαA (Millipore,
1:1000), anti-Rac1 and GTP-Rac1 (Santa Cruz and NewEast Biosci-
ence respectively, 1:500); anti-ERK and p-ERK, anti-STAT3 and
p-705Tyr-STAT3 (Cell Signaling Technology, 1:1000); anti-Cyclin
D1 and anti-Cyclin D3 (Bioworlde, 1:500); anti-β-actin (ZSGB-BIO,
1:1000), anti-ﬂag, anti-myc, anti-HA (Sigma, 1:1000); anti-β-
Tubulin and anti-lamin A/C (Bioworlde, 1:1000). TIPE2 was detected
using a speciﬁc antibody as described previously [18]. Immunoblotting
1576 G. Zhang et al. / Biochimica et Biophysica Acta 1852 (2015) 1574–1584was conducted by incubating the membranes with primary antibodies at
4 °C overnight followed by secondary antibodies (goat anti-rabbit Ig G or
goat anti-mouse Ig G, 1:1000) conjugatedwith peroxidase for 1 h at room
temperature. After washing, bound peroxidase activity was detected
by the ECL detection system (ECL, F-cheiBIsi.6pro, DNR) using the
SuperSignal West Pico kit (Pierce Biotechnology). Densitometric analysis
was performed using Image-Pro Plus software (Media Cybernetics, Silver
Spring, MD).2.10. PBD pull-down assay
VSMCs (2 × 105 cells/well) were cultured in 6-well dishes for 24 h.
Then cells were made quiescent by incubation with serum-free DMEM
for 24 h, and stimulated with PDGF-BB (10 ng/mL) for 15 or 30 min.
Then cells were washed in PBS and lysed in PBD lysis buffer (50 mM
Tris, pH 7.5, 10 mMMgCl2, 0.2 M NaCl, 0.5% Nonidet P-40, and 1× pro-
tease inhibitors mixture) (Roche). The lysate was incubated with 20 μg
of p21-activated kinase (PAK)-GST protein beads (Cytoskeleton) for
30 min at 4 °C. After washing, protein on beads and in total cell lysates
was subjected to Western blot to determine the level of active Rac1.2.11. Immunoﬂuorescence and microscopy
QuiescentWT or TIPE2−/− VSMCs, HEK293 transfected with pEGFP-
mTIPE2/HA-STAT3-C or pEGFP/HA-STAT3-C, HEK293 transfected with
Rac1-siRNA/HA-STAT3-C or MOCK/HA-STAT3-C were treated with
10 ng/mL of PDGF-BB for 15 min and then were washed, ﬁxed in 4%
paraformaldehyde, and permeabilized with 0.5% Triton X-100. Cells
were blocked with goat serum and incubated with the ﬁrst antibody
followed by goat anti-rabbit antibody. Rabbit anti-STAT3 (Cell Signaling
Technology, 1:100) and rabbit anti-HA (Sigma, 1:500) antibodies (Abs)
were used as the ﬁrst Abs. Alexa 488- or rhodamine-conjugated goat
anti-rabbit immunoglobulin (Molecular Probes) was used as the sec-
ondary Ab. DNA staining was performed using 4, 6-diamino-2-
phenylindole (DAPI, Roche).
Fixed ﬂuorescent images were analyzed on an optical microscope
(Olympus BX51, Japan). 10–15 high-power ﬁelds were evaluated, and
representative images were shown. Experiments were repeated three
times, and each treatment was done in duplicate.2.12. Subcellular fractionation
Cytoplasmic and nuclear proteins were isolated with NE-PER
(R) Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnolo-
gy). In brief, cells were washed with cold PBS and fully suspended in
ice-cold CER I by vortex on the highest setting for 15 s, followed by incu-
bation on ice for 10min. Homogenates weremixedwith ice-cold CER II,
incubated on ice for 1min and then centrifuged at 16,000×g for 5min at
4 °C. The supernatants (cytosol) were collected and the pellets were re-
suspended in ice-cold NER and incubated on ice for 40min, vortexed for
15 s every 10 min. The lysates were again centrifuged at 16,000 ×g for
5 min, and the supernatants (nucleus) were collected. The distributions
of proteins in the cytosol and nucleus fractions were analyzed byWest-
ern blot.2.13. Statistical analysis
All analyses were performed using SPSS 16.0 (SPSS Inc.). Data were
expressed asmean±SEM. Student's t-test was used to compare contin-
uous data for two groups, ANOVA was used for comparisons among
multiple groups, and LSD post-hoc test was used for multiple compari-
sons. P b 0.05 was considered statistically signiﬁcant. All experiments
were repeated at least three times.3. Results
3.1. TIPE2 suppresses injury-induced restenosis in mice
To evaluate the role of TIPE2 in restenosis, ligation-induced vascular
injury was generated in the left carotid artery ofWT and TIPE2−/−mice.
As shown in Fig. 1A, signiﬁcantly enhanced neointimal formation was
observed in TIPE2−/−mice at days 14 and 21 after vascular injury com-
pared withWTmice. Furthermore, in injury-induced restenosis groups,
neointimal area was signiﬁcantly larger in TIPE2−/−mice thanWT con-
trols, 1.9-fold larger at day 14, and 3.7-fold larger at day 21 after injury
(Fig. 1B left panel). Consistent with these results, an increased I/M (Inti-
mal/Media) ratio in TIPE2−/−micewas observed at day 14 (TIPE2−/− vs.
WT, 0.739 ± 0.1075 (n = 5) vs. 0.416 ± 0.0601 (n = 5), P= 0.0252)
and day 21 (TIPE2−/− vs. WT, 2.422 ± 0.2101 (n = 5) vs. 0.517 ±
0.0812 (n= 5), P b 0.0001) after injury (Fig. 1B, right panel). These re-
sults suggest that TIPE2 deﬁciency accelerates the restenosis response
to vascular injury.
To conﬁrm the inhibitory effects of TIPE2 on restenosis, therapeutic
experiments were performed with recombinant adenovirus-mediated
overexpression ofmTIPE2 in injured vasculature ofWTmice. The results
showed that TIPE2 signiﬁcantly delayed injury-induced neointimal
formation (Fig. 1C, D). Six weeks after injury, both of neointimal area
and I/M ratiowere remarkably reduced by TIPE2-expressing adenovirus
(Fig. 1D, Ad-GFP vs. Ad-mTIPE2, 37.78 ± 2.402 × 103 μm2 (n = 8) vs.
19.36 ± 2.905 × 103 μm2 (n = 12), P = 0.0081 for neointimal area;
1.885 ± 0.1794 (n = 8) vs. 0.8888 ± 0.1374 (n = 12), P= 0.0116 for
I/M ratio). These data further demonstrated that TIPE2 could lessen re-
stenosis after injury.
Recent studies showed that wire injury-induced neointimal hyper-
plasia could primarily be attributed to the proliferation of VSMCs [6,
19]. Our previous study showed that TIPE2 played atheroprotective
roles by regulating phenotypic switching of VSMCs [14]. Therefore, we
examined the cellular proliferation in carotid arteries by EDU staining.
Intriguing, EDU-positive cells in arteries were signiﬁcantly increased
in TIPE2−/−mice (Fig. 1E, left panel). At day 7 after injury, a higher per-
centage of EDU-positive cells was observed in TIPE2−/−mice than WT
mice controls (Fig. 1E, right panel, TIPE2−/− vs. WT, 21.69 ± 2.639%
(n = 5) vs. 9.58 ± 1.625% (n = 5), P = 0.0175). These data suggest
that TIPE2 might play suppressive roles on restenosis via inhibiting
VSMC proliferation.
Furthermore, TIPE2 can promote tumor cell death [10]. We don't
know whether the enhanced neointima formation in TIPE2−/−mice is
associated with VSMC apoptosis. To address this issue, we detected
the apoptotic cells in the arteries through TUNEL assay. As shown in
Fig. 1F, both TIPE2−/−mice andWTmice exhibited low levels of apopto-
sis, and there was no signiﬁcant difference between these two groups
(TIPE2−/− vs. WT, 2.37 ± 0.841% (n = 4) vs. 2.57 ± 0.673% (n = 3),
P = 0.8565). These data suggest that constitutive TIPE2 inhibited
VSMC proliferation without affecting apoptosis in the pathologic condi-
tion of experimental restenosis.
3.2. TIPE2 is markedly upregulated in VSMC response to PDGF-BB
stimulation and injury
To study the mechanism of TIPE2 in VSMC proliferation, primary
VSMCs were isolated fromWT and TIPE2−/−mice and identiﬁed using
an antibody directed against SMαA protein by ﬂow cytometry analysis.
We found that more than 95% of isolated cells (WT and TIPE2−/−
VSMCs) were SMαA-positive (Fig. 2A).
Platelet-derived growth factor (PDGF) plays a central role in the
pathogenesis of intimal hyperplasia and mediates VSMC proliferation
[1]. To evaluate the effect of PDGF on TIPE2 expression, WT VSMCs
were grown in DMEM medium containing 10% FBS in the absence or
presence of 10 ng/mL PDGF-BB. As shown in Fig. 2B and C, both the
mRNA and protein levels of TIPE2 in WT but not TIPE2−/− VSMCs
Fig. 1. TIPE2 suppresses injury-induced neointimal formation inmice. (A) Representativemicrophotographs of hematoxylin eosin (HE)-stained uninjured or injured carotid arterial inWT
and TIPE2−/−mice at days 7, 14, and 21 after injury. Scale bar indicates 50 μm. (B) Quantitative analysis of intimal area (n= 5) and I/M ratio (n= 5) as shown in (A). (C) Representative
microphotographs of HE-stained neointimal sections obtained from carotid-injuredWTmice at day 42 after adenovirus-mediated gene transfer of murine TIPE2 (mTIPE2). Scale bars in-
dicate 50 μm. (D) Quantitative analysis of the intimal area (Ad-GFP, n = 8; Ad-mTIPE2, n = 12) as shown in (C). (E) Representative magniﬁcations (left panel) and quantitative analysis
(right panel, n = 5) of the EDU incorporation in VSMCs of carotids at day 7 after injury. Scale bars indicate 50 μm. (F) Representative magniﬁcations (left panel) and quantitative analysis
(right panel, n = 3 for WT, n = 4 for TIPE2−/−mice) of the TUNEL staining in VSMCs of carotids at day 14 after injury. Scale bars indicate 20 μm.
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with this ﬁnding, TIPE2 was upregulated in response to injury in vascu-
lar media of WT mice (Fig. 2D). However, the increased tendency ofTIPE2 was lessened at day 14 compared with day 7 after injury
(Fig. 2D), providing a plausible explanation that WT mice couldn't
completely avoid injury-induced restenosis (Fig. 1C, D, Ad-GFP
Fig. 2. TIPE2 is upregulated in VSMCs in response to PDGF-BB or injury. (A) Flow cytometric analysis of culturedVSMCs. (B) TIPE2mRNA levels in VSMCs treatedwith PDGF-BB (10 ng/mL)
for the indicated time points weremeasured by real-time PCR. **P b 0.005, n= 3. (C) Levels of TIPE2 protein inWT and TIPE2−/− VSMCs treatedwith PDGF-BB (10 ng/mL)were detected
by immunoblotting;β-actin served as a loading control. One representative result of three independent experimentswas demonstrated. (D) Expression of TIPE2 protein in injured carotids
obtained fromWT (n = 5) and TIPE2−/− (n = 5) mice at days 7 and 14 post vascular injury was determined by immunoblotting; β-actin served as a loading control.
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restenosis by regulating VSMC functions.3.3. TIPE2 deﬁciency promotes VSMC proliferation by upregulating Cyclin
D1 and D3 expression
To investigate the functional role of TIPE2 on VSMC proliferation, we
examined the effect of TIPE2 deﬁciency on these PDGF-BB-induced
cellular processes. As shown in Fig. 3A, TIPE2 deﬁciency signiﬁcantly
enhanced VSMC proliferation either in the presence or absence of
PDGF-BB stimuli. Fluorescence-activated cell-sorting analysis of PI-
stained cells also indicated a cell cycle arrest in the G0/G1 phase caused
by TIPE2 (Fig. 3B). As shown in Fig. 3C, TIPE2 deﬁciency increased the
proportion of VSMC in S phase (untreated: TIPE2−/− vs. WT, 12.17 ±
0.436% (n = 5) vs. 6.00 ± 0.351% (n = 5), P = 0.0004; PDGF-BB-
treated: 41.61 ± 2.138% (n = 5) vs. 19.12 ± 0.944% (n = 5), P =
0.0007), and simultaneously reduced the percentage of cells in the
G0/G1 phase (untreated: TIPE2−/− vs. WT, 82.68 ± 1.168% (n = 5) vs.
90.29 ± 1.536% (n = 5), P = 0.0169; PDGF-BB-treated: 50.69 ±
1.112% (n= 5) vs. 76.11 ± 1.894% (n= 5), P=0.0003). In accordance
with these ﬁndings, TIPE2 ablation increased expression of Cyclins D1
and D3, which are essential for the G1/S phase transition, in PDGF-BB-
treated VSMCs (Fig. 3D, E) and injured vascular media in mice
(Fig. 3F). The dedifferentiation state characterized by downregula-
tion of differentiated marker genes, such as SMαA, SM22α, and
SMMHC, is necessary for VSMC proliferation. Therefore, we deter-
mined the expression level of SMαA, and found a marked decrease
in untreated or PDGF-BB-treated VSMCs and injured vascular
media obtained from TIPE2-deﬁcient mice (Fig. 3D, E). These data
suggest that TIPE2 may inhibit VSMC proliferation by dampening
Cyclin D1 and D3 expression.3.4. TIPE2 signiﬁcantly suppresses VSMC proliferation through sequestering
cells in the G0/G1 phase
As determined by cell counting kit-8 analysis, TIPE2 overexpression
remarkably restrained the viability of VSMCs both under resting and
PDGF-BB-stimulated conditions compared with pRK5 control or R24A
mutant group (Fig. 4A). Fluorescence-activated cell-sorting analysis
showed that TIPE2 sequestered VSMCs in the G0/G1 phase (Fig. 4B and
C), while R24A, a TIPE2mutant that is not able to bind to Rac1 [9], failed
to do so. This result is consistent with the effect of TIPE2 on Cyclins. As
shown in Fig. 4D and E, both at the levels of transcription and transla-
tion, TIPE2 but not R24A overexpression signiﬁcantly inhibited Cyclin
D1 and D3 expression in VSMCs treated with or without PDGF-BB.
TIPE2 overexpression signiﬁcantly increased SMαA expression. As a
result the dedifferentiation of TIPE2-overexpressed VSMCs in response
to PDGF-BB stimulation was repressed. However, R24A had no effect
on these processes (Fig. 4E). These data indicate that TIPE2 could in-
hibit VSMC survival by arresting cells in the G0/G1 phase in a Rac1-
dependent manner.3.5. TIPE2 regulates VSMC proliferation via Rac-STAT3 and Rac-ERK1/2 sig-
naling pathways
Rac signaling is involved in the control of cell–cell adhesions, cell-
matrix adhesions, cell migration, cell cycle progression, and cellular
transformation [20]. Previous reports pointed out that TIPE2 inhibited
Rac membrane translocation, Rac activation and downstream signaling
[9]. Therefore, we examined the effect of TIPE2 on Rac1 activation
in VSMCs. As shown in Fig. 5A, TIPE2 deﬁciency in VSMCs markedly
enhanced Rac1 activation in response to PDGF-BB stimulation.Whereas
overexpression of TIPE2 signiﬁcantly inhibited Rac1 activation (Fig. 5B).
Fig. 3. TIPE2 deﬁciency enhanced PDGF-BB- and injury-induced Cyclin D expression and subsequent VSMC proliferation. (A) Proliferation ability of WT and TIPE2−/− VSMCs cultured in
the absence or presence of PDGF-BB was examined using cell counting kit-8. *P b 0.05, **P b 0.005, for PDGF-BB-stimulated WT vs TIPE2−/− VSMCs (n = 5); #P b 0.005, ##P b 0.005, for
non-stimulated WT vs TIPE2−/− VSMCs (n = 5). (B) Representative graphs of cell cycle distribution determined by ﬂow cytometric evaluation. (C) Quantiﬁcation of VSMCs in G0/G1,
S, or G2/M phase, as determined by ﬂow cytometric evaluation. *P b 0.05, ***P b 0.001, n = 5. (D) Expression of Cyclin D1 and D3 mRNA in WT and TIPE2−/− VSMCs stimulated with
PDGF-BB for different times was examined by real-time PCR. *P b 0.05, **P b 0.005, ***P b 0.001, n = 3. (E) Levels of Cyclins D1 and D3 and SMαA proteins in PDGF-BB-treated WT and
TIPE2−/− VSMCs were examined by immunoblotting. One representative result of three independent experiments was shown. (F) Expression of Cyclins D1 and D3 and SMαA proteins
in injured carotids obtained fromWT (n = 5) and TIPE2−/− (n = 5) mice at days 7 and 14 after injury was examined by immunoblotting.
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We also found that the phosphorylation levels of STAT3 (at Try705) and
ERK1/2 were strikingly enhanced in TIPE2-deﬁcient VSMCs (Fig. 5A),
but were markedly decreased by TIPE2 overexpression (Fig. 5B). Fur-
thermore, the enhanced activation of ERK1/2 and STAT3 in TIPE2-
deﬁcient VSMCs could be eliminated by NSC23766, a speciﬁc inhibitor
that blocks Rac1 activation (Fig. 5C). Interestingly, as shown in Fig. 5D,
the mRNA levels of Cyclins D1 and D3 were signiﬁcantly decreased by
PD98059 and Stattic (speciﬁc inhibitors for ERK1/2 and STAT3, res-
pectively). Furthermore, the difference of expression levels between
WT and TIPE2−/− VSMCs was also eliminated. These data strongly sug-
gest that TIPE2 modulates VSMC proliferation through Rac1-STAT3 or/
and ERK1/2 signaling pathways.3.6. TIPE2 blocks STAT3 nuclear translocation in a Rac1 dependent manner
Activated STAT3 form homo- or hetero-dimers, and enter the nuc-
leus, where they regulate expression of their target genes [21,22]. To de-
termine the effect of TIPE2 on nuclear translocation of activated STAT3,
subcellular distribution of STAT3 inWT and TIPE2−/− VSMCswas tested
by immunoﬂuorescence and immunoblotting. As shown in Fig. 6A
and B, the levels of intranuclear STAT3 were signiﬁcantly increased in
TIPE2−/− VSMCs compared with WT cells treated with or without
PDGF-BB. Importantly, the accumulation of STAT3 in nucleus was ac-
companied by the decrease in cytoplasm (Fig. 6B), strongly indicating
that TIPE2does not affect the expression of STAT3 but blocks theprocess
of nuclear translocation.
Fig. 4. TIPE2 suppresses D-type Cyclin expression and VSMCs proliferation. (A) The viability of VSMCs expressing mTIPE2 or R24A was examined using cell counting kit-8. *P b 0.05,
**P b 0.005, n = 3. (B and C) Analysis of cell cycle of mTIPE2- or R24A-transfected VSMCs by ﬂow cytometry. Cells transfected with pRK5 vectors were used as a control. n = 5.
(D) The mRNA levels of Cyclins D1 and D3 in VSMCs expressing mTIPE2 or R24Awere analyzed by real-time PCR. (F) The protein levels of Cyclins D1 and D3 and SMαA in VSMCs expressing
mTIPE2 or R24A were analyzed by Western blot.
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tant of STAT3 characterized by dimerizing and entering nucleus sponta-
neously [23,24], was introduced into HEK293 cells. The spontaneous
nuclear translocation of STAT3-C could be blocked by Rac1-siRNA
(Fig. 6C, D). Therefore, we co-introduced STAT3-C and pRK5-mTIPE2
in HEK293 cells and found that overexpression of TIPE2 could signiﬁ-
cantly suppress nucleus translocation of STAT3-C (Fig. 6E). Further-
more, distribution of STAT3-C analyzed by immunoblotting revealed
that both TIPE2 and Rac1-siRNA diminished accumulation of STAT3-C
in the nucleus, and this inhibitory effect of TIPE2 could almost com-
pletely be abolished by Rac1-Q61L, a constitutively active form of Rac1
(Fig. 6F, left panel). This inhibitory effect and underlying mechanism
of TIPE2 on STAT3-C nuclear translocation observed in HEK293 was
further conﬁrmed in WT VSMCs (Fig. 6F, right panel). Taken together,
in addition to inhibiting STAT3 activation, TIPE2 also plays a negative
role in nucleus translocation of STAT3.
4. Discussion
Excessive proliferation of VSMCs in the arterial wall plays a promi-
nent role in the pathogenesis of vascular disorders such as atherosclero-
sis, postangioplasty restenosis, bypass vein graft failure, and cardiacallograft vasculopathy [25,26]. Elucidation of the key mechanisms
controlling VSMC proliferation will help understand cellular responses
to vascular injury and develop safe and efﬁcient therapeutic strategies
for the prevention of vascular proliferative diseases.
In this study we demonstrate that TIPE2, a negative regulator of in-
ﬂammation and oncogenesis, prevents the development of experimen-
tal restenosis by inhibiting VSMC proliferation. We provide evidence
that TIPE2 also inhibits Rac1 activation in VSMCs and interferes with
downstream signaling to STAT3 and ERK1/2 in response to injury ormi-
togenic stimuli. Both STAT3 and ERK1/2 signal pathways are reported to
be essential for the induction of cell cycle entry [26–29]. In concert with
the regulation of STAT3 and ERK1/2, TIPE2 prevents the transcriptional
activation of G1 phase Cyclins and subsequent G1/S phase transition,
resulting in growth inhibition of VSMCs (Fig. 7).
The key ﬁndings of the present study are as follows: (1) Restenosis
formation was enhanced in TIPE2−/−mice after vascular injury, which
was related to an increased ratio of EDU-positive VSMCs in vivo.
(2) TIPE2 expression was upregulated in response to injury and PDGF-
BB stimulation in VSMCs, but it failed to completely inhibit VSMC prolif-
eration and neointimal formation. (3) Adenovirus-mediated gene trans-
fer of TIPE2 in vivo signiﬁcantly delayed neointial formation. (4) TIPE2
prevented PDGF-BB-induced upregulation of Cyclins D1 and D3, and
Fig. 5. TIPE2 regulates Cyclin D1 and D3 expression in a Rac-STAT3 and Rac-ERK1/2 dependent manner. (A) PDGF-BB-induced activation of Rac1, STAT3, and ERK1/2 inWT and TIPE2−/−
VSMCs were examined by immunoblotting. One representative result of three independent experiments was shown (left panel). The results of quantitative analysis for the activation of
Rac1, STAT3 and ERK1/2were shown (right panel, n= 3 per group). *P b 0.05, **P b 0.005, ns indicated no signiﬁcant difference. (B) Representative immunoblotting images for GTP-Rac1,
p-STAT3, and p-ERK1/2 in mTIPE2- and R24A-transfected VSMCs (left panel). The results of quantitative analysis for the activation of Rac1, STAT3 and ERK1/2 were shown (right panel,
n=3per group). *P b 0.05, **P b 0.005, ns indicatedno signiﬁcant difference. (C) Activation of STAT3 and ERK1/2 inWTand TIPE2−/−VSMCs incubatedwith NSC23766 (a speciﬁc inhibitor
for Rac1, 50 μM) following PDGF-BB stimuli was determined by immunoblotting (left panel). The results of quantitative analysis for the activation of Rac1, STAT3 and ERK1/2were shown
(right panel, n= 3 per group). *P b 0.05, ns indicated no signiﬁcant difference. (D) ThemRNA levels of Cyclins D1 and D3 inWT and TIPE2−/− VSMCs stimulatedwith PD98059 (a speciﬁc
inhibitor of ERK1/2, 20 μM) plus Stattic (a speciﬁc compound that inhibits the activation and nucleus translocation of STAT3, 10 μM) following PDGF-BB treatmentwere analyzed by real-
time PCR. ***P b 0.001, **P b 0.005, n = 3.
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results, we conclude that TIPE2 limits neointimal formation after vascu-
lar injury by regulating the proliferation of VSMCs; therefore, TIPE2may
be a new therapeutic target for the prevention of restenosis.
Coronary artery disease is the leading cause of mortality and mor-
bidity in the developed world [30]. To date, percutaneous coronary
intervention especially coronary stent placement is the preferred thera-
peuticmethod for coronary artery diseases [26,31–33]. However, sever-
al major clinical drawbacks still persist, including restenosis within the
treated vessel [30,34]. Therefore, it is important to dissect the molec-
ular mechanisms of restenosis to improve the safety and efﬁcacy of PCI.
Restenosis is mainly due to neointima formation and constrictive remod-
eling of blood vessel, which is caused primarily by the effects of VSMCproliferation andmigration [35]. Growth factors such as PDGF and FGF re-
leased during the arterial injury caused by PCI play a central role in the
pathogenesis of restenosis andmediate many important cellular process-
es including VSMC proliferation [1]. However, themolecularmechanisms
controlling growth factor-induced VSMC proliferation and subsequent
neointimal hyperplasia remain to be elucidated. PDGF is an important
growth factor released after PCI and vascular injury and is related to
VSMC proliferation and ensuing restenosis. Therefore, screening of mole-
cules with potential to limit inappropriate proliferation of VSMCs in a
PDGF shedding condition may be beneﬁcial. We previously reported
that TIPE2 acts as an atheroprotective molecule by inhibiting ox-LDL-
induced dedifferentiation, migration and proliferation of VSMCs [14].
In this study we found for the ﬁrst time that TIPE2 inhibited PDGF-BB-
Fig. 6. TIPE2 modulates STAT3 nuclear translocation in a Rac1 dependent manner. (A) Nuclear transport of STAT3 in WT and TIPE2−/− VSMCs treated with PDGF-BB was evaluated by
immunoﬂuorescence staining. Scale bars indicate 20 μm. (B) PDGF-BB-induced redistribution of STAT3 in WT and TIPE2−/− VSMCs were examined by immunoblotting. β-Tubulin and
Lamine A/C served as loading controls for cytoplasm and nucleus proteins, respectively. Three independent experiments were performed and one representative was shown. (C) Rac1
protein expression in HEK293 transfected with siRNA-Rac1 or siRNA-control (MOCK) was determined by immunoblotting. (D) Subcellular localization of HA-STAT3-C in HEK293 cells
after addition of siRNA-Rac1 orMOCKwas examined by immunoﬂuorescence staining. Scale bars indicate 20 μm. (E) Subcellular localization of HA-STAT3-C inHEK293 cells after addition
of EGFP-mTIPE2 or EGFP. Scale bars indicate 20 μm. (F) Subcellular distribution of HA-STAT3-C inHEK293 cells (left panel) andWTVSMCs (right panel) transfectedwith Flag-mTIPE2 plus
Myc-Rac1-Q61L, Flag-mTIPE2 only, or siRNA-Rac1was detected by immunoblotting.β-Tubulin and Lamine A/C served as loading controls for total and nucleus protein, respectively. Three
independent experiments were performed and one representative was shown.
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stream signaling to ERK1/2 and STAT3. Regulation of the expression
level of cell cycle regulatory molecules (including Cyclins, Cdks, Cdkinhibitors) is one of the principal mechanisms for inhibiting cell growth.
Previous studies have reported that ERK1/2 and STAT3 modulated Cyclin
D1 and D3 transcription and ensuing proliferation of VSMCs [26,27].
Fig. 7. Proposed roles of TIPE2 in vascular remodeling. In response to injury and growth factors such as PDGF-BB, Rac1was activated in VSMCs. Activated Rac1 not only promoted the phos-
phorylation of both STAT3 and ERK1/2 but also advanced nucleus translocation of activated STAT3. STAT3 collaboratedwith ERK1/2 signaling to upregulate the expression of CyclinD1 and
Cyclin D3, both of which were required for the G1/S phase transition and cell growth. TIPE2 acted as a negative regulator of the aforementioned processes by inhibiting Rac1 activation,
herein limited the proliferation of VSMCs and the ensuing restenosis formation.
1583G. Zhang et al. / Biochimica et Biophysica Acta 1852 (2015) 1574–1584Consistent with this, here we showed that TIPE2 downregulates
both Cyclin D1 and Cyclin D3 genes through ERK and STAT3 depen-
dent mechanisms.
TIPE2 was ﬁrst identiﬁed as a negative regulator of both inﬂamma-
tion and ras-related neoplasia [8–10]. TIPE2-dependent mechanism
for anti-inﬂammation and anti-tumorgenesis has been well elucidated.
However, less is known about TIPE2 in the modulation of cellular pro-
cesses in non-immune organs. Our previous report provided initial evi-
dence that TIPE2 inhibited ox-LDL-induced dedifferentiation of VSMCs
in a manner dependent on ERK1/2 and P38 signal pathway. However,
the upstream molecular mechanism by which TIPE2 modulated MAPK
signaling is not completely clear. In our present study, we further demon-
strated that TIPE2 affects PDGF-stimulated activation of ERK1/2 and
STAT3, and ensuing nucleus translocation of STAT3 in VSMCs by interfer-
ingwith Rac1. Rac is a member of the Rho family of small GTPases, which
acts as a molecular switch to control a wide array of cellular functions
[20]. Rac GTPase pathways is involved in various pathological conditions
in humans, including tumorigenesis and some immune related diseases
[36]. Therefore, TIPE2, as a novel inhibitory molecule of Rac, likely plays
crucial roles in the aforementioned Rac-related diseases.
In conclusion, our data indicate that TIPE2 expressed in VSMCs plays a
vascular protective role during the pathological process of injury-induced
restenosis by negatively regulating PDGF-stimulated cellular proliferation
(Fig. 7). These ﬁndings may not only advance our understanding of the
molecular mechanisms controlling VSMC proliferation and subsequent
neointimal hyperplasia, but also lead to the development of TIPE2-based
strategies for treating restenosis.
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